-
公开(公告)号：US20120022119A1
公开(公告)日：2012-01-26
申请号：US13129078
申请日：2009-11-16
申请人： John Howard Hutchinson , Nicholas Simon Stock , Jeffrey Roger Roppe , Brian Andrew Stearns , Timothy Parr
发明人： John Howard Hutchinson , Nicholas Simon Stock , Jeffrey Roger Roppe , Brian Andrew Stearns , Timothy Parr
IPC分类号： A61K31/4245 , C07D231/12 , C07D271/06 , A61K31/4155 , A61K31/415 , A61P11/06 , A61P17/06 , A61P9/12 , A61P11/14 , A61P9/00 , A61P35/00 , A61P19/02 , A61P29/00 , A61P9/10 , A61P11/08 , A61P11/12 , A61P11/02 , A61P37/08 , A61P11/00 , A61P1/00 , A61P7/10 , A61P43/00 , C07D403/06
CPC分类号： C07D403/06 , A61K31/4174 , A61K31/4178 , C07D231/12 , C07D271/06
摘要： Described herein are heteroaryl compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions and medicaments that include the heteroaryl compounds described. Also described herein are methods of using such antagonists of PGD2 receptors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2-mediated conditions or diseases.
摘要翻译： 本文描述的是作为PGD 2受体拮抗剂的杂芳基化合物。 还描述了包括所述杂芳基化合物的药物组合物和药物。 本文还描述了使用这种PGD2受体单独的和与其它化合物组合的拮抗剂用于治疗呼吸，心血管和其它PGD2依赖性或PGD2介导的病症或疾病的方法。
-
公开(公告)号：US20100298368A1
公开(公告)日：2010-11-25
申请号：US12741805
申请日：2008-10-31
IPC分类号： A61K31/438 , C07D295/027 , C07D295/26 , A61P11/06 , A61P29/00 , A61P9/12 , A61P19/02 , A61P17/06 , A61P35/00 , A61P11/14 , A61P9/00 , A61P37/08 , A61P11/00 , A61P9/10
CPC分类号： C07D257/08 , C07C311/20 , C07C2603/94 , C07D221/20 , C07D407/04
摘要： Described herein are compounds and pharmaceutical compositions containing such compounds that modulate the PGD2 activated chemoattractant receptor-homologous molecule expressed on TH2 cells (CRTH2). Also described herein are methods of using such CRTH2 modulators, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2 mediated conditions or diseases.
摘要翻译： 本文描述了含有调节在TH2细胞（CRTH2）上表达的PGD2激活的化学引诱物受体同源分子的化合物和药物组合物。 本文还描述了使用这样的CRTH2调节剂单独和与其它化合物组合用于治疗呼吸，心血管和其它PGD2依赖性或PGD2介导的病症或疾病的方法。
-
公开(公告)号：US07919621B2
公开(公告)日：2011-04-05
申请号：US11626222
申请日：2007-01-23
IPC分类号： C07D487/06 , A61K31/4745 , A61K31/4738
CPC分类号： C07D487/04 , C07D471/04
摘要： Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of 5-lipoxygenase (5-LO). Also described herein are methods of using such 5-LO inhibitors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions, diseases, or disorders.
摘要翻译： 本文描述了含有抑制5-脂氧合酶（5-LO）活性的这些化合物的化合物和药物组合物。 本文还描述了使用这种单独的和与其它化合物组合的这种5-LO抑制剂来治疗呼吸，心血管和其它白三烯依赖性或白细胞三烯介导的病症，疾病或病症的方法。
-
公开(公告)号：US20110112134A1
公开(公告)日：2011-05-12
申请号：US12991747
申请日：2009-01-15
IPC分类号： A61K31/4375 , C07D471/14 , A61P11/00 , A61P29/00 , A61P37/08 , A61P11/06 , A61P9/12 , A61P19/02 , A61P17/06 , A61P9/10 , A61P35/00 , A61P11/14 , A61P7/10
CPC分类号： C07D471/14
摘要： Described herein are compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions and medicaments that include the compounds described herein that are antagonists of PGD2 receptors. Also described herein are methods of using such antagonists of PGD2 receptors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2-mediated conditions or diseases.
摘要翻译： 本文描述的是作为PGD 2受体拮抗剂的化合物。 还描述了包括作为PGD 2受体的拮抗剂的本文所述的化合物的药物组合物和药物。 本文还描述了使用这种PGD2受体单独的和与其它化合物组合的拮抗剂用于治疗呼吸，心血管和其它PGD2依赖性或PGD2介导的病症或疾病的方法。
-
公开(公告)号：US09688624B2
公开(公告)日：2017-06-27
申请号：US13519292
申请日：2011-01-05
IPC分类号： C07C323/41
CPC分类号： C07C323/41 , C07B2200/13
摘要： Described herein is the DP2 antagonist 2-(3-(2-((tert-butylthio)methyl)-4-(2,2-dimethyl-propionylamino)phenoxy)-4-methoxyphenyl)acetic acid, or a pharmaceutically acceptable salt thereof. Also described are methods of preparing the DP2 antagonist, or a pharmaceutically acceptable salt thereof. Also described herein are pharmaceutical compositions suitable for administration to a mammal that include the DP2 antagonist, or a pharmaceutically acceptable salt thereof, and methods of using such pharmaceutical compositions for treating respiratory diseases or conditions, allergic diseases or conditions, inflammatory diseases or conditions, as well as other prostaglandin D2-dependent or prostaglandin D2-mediated diseases or conditions.
-
公开(公告)号：US20120214840A1
公开(公告)日：2012-08-23
申请号：US13497519
申请日：2010-09-23
IPC分类号： A61K31/437 , A61P29/00 , A61P11/00 , A61P3/00 , A61P11/06 , A61P9/10 , A61P19/02 , A61P35/00 , C07D471/04 , A61P9/00
CPC分类号： C07D471/04
摘要： Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of 5-lipoxygenase (5-LO). Also described herein are methods of using such 5-LO inhibitors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions, diseases, or disorders.
摘要翻译： 本文描述了含有抑制5-脂氧合酶（5-LO）活性的这些化合物的化合物和药物组合物。 本文还描述了使用这种单独的和与其它化合物组合的这种5-LO抑制剂来治疗呼吸，心血管和其它白三烯依赖性或白细胞三烯介导的病症，疾病或病症的方法。
-
公开(公告)号：US08815917B2
公开(公告)日：2014-08-26
申请号：US12846690
申请日：2010-07-29
IPC分类号： A61K31/4418 , A61K31/195 , C07D213/64 , C07C229/00
CPC分类号： A61K31/195
摘要： Described herein is the DP2 antagonist [2′-(3-benzyl-1-ethyl-ureidomethyl)-6-methoxy-4′-trifluoromethyl-biphenyl-3-yl]-acetic acid, or a pharmaceutically acceptable salt thereof. Also described are methods of preparing the DP2 antagonist, or a pharmaceutically acceptable salt thereof. Also described herein are pharmaceutical compositions suitable for administration to a mammal that include the DP2 antagonist, or a pharmaceutically acceptable salt thereof, and methods of using such pharmaceutical compositions for treating respiratory diseases or conditions, allergic diseases or conditions, inflammatory diseases or conditions, as well as other prostaglandin D2-dependent or prostaglandin D2-mediated diseases or conditions.
摘要翻译： 本文描述的是DP2拮抗剂[2' - （3-苄基-1-乙基 - 脲基甲基）-6-甲氧基-4'-三氟甲基 - 联苯-3-基] - 乙酸或其药学上可接受的盐。 还描述了制备DP2拮抗剂或其药学上可接受的盐的方法。 本文还描述了适用于给予哺乳动物包括DP2拮抗剂或其药学上可接受的盐的药物组合物，以及使用这些药物组合物治疗呼吸系统疾病或病症，过敏性疾病或病症，炎性疾病或病症的方法，如 以及其他前列腺素D2依赖性或前列腺素D2介导的疾病或病症。
-
公开(公告)号：US20130053444A1
公开(公告)日：2013-02-28
申请号：US13519292
申请日：2011-01-05
IPC分类号： A61K31/196 , A61P11/00 , A61P29/00 , A61P11/02 , A61P11/06 , A61P37/00 , A61P27/02 , A61P17/00 , C07C321/10 , A61P37/08
CPC分类号： C07C323/41 , C07B2200/13
摘要： Described herein is the DP2 anatgonist 2-(3-(2-((tert-butylthio)methyl)-4-(2,2-dimethyl-propionylamino)phenoxy)-4-methoxyphenyl)acetic acid, or a pharmaceutically acceptable salt thereof. Also described are methods of preparing the DP2 anatgonist, or a pharmaceutically acceptable salt thereof. Also described herein are pharmaceutical compositions suitable for administration to a mammal that include the DP2 anatgonist, or a pharmaceutically acceptable salt thereof, and methods of using such pharmaceutical compositions for treating respiratory diseases or conditions, allergic diseases or conditions, inflammatory diseases or conditions, as well as other prostaglandin D2-dependent or prostaglandin D2-mediated diseases or conditions.
摘要翻译： 本文描述的是DP2阴离子表面活性剂2-（3-（2 - （（叔丁硫基）甲基）-4-（2,2-二甲基 - 丙酰基氨基）苯氧基）-4-甲氧基苯基）乙酸或其药学上可接受的盐 。 还描述了制备DP2拮抗剂或其药学上可接受的盐的方法。 本文还描述了适用于给予哺乳动物的药物组合物，其包括DP2拮抗剂或其药学上可接受的盐，以及使用这些药物组合物治疗呼吸系统疾病或病症，过敏性疾病或病症，炎性疾病或病症的方法，如 以及其他前列腺素D2依赖性或前列腺素D2介导的疾病或病症。
-
49.发明申请TRICYCLIC COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS 审中-公开作为PROSTAGLANDIN D2受体拮抗剂的三聚体化合物公开(公告)号：US20120004233A1
公开(公告)日：2012-01-05
申请号：US13145322
申请日：2010-01-26
申请人： Brian Andrew Stearns , Ryan Clark
发明人： Brian Andrew Stearns , Ryan Clark
IPC分类号： A61K31/53 , C07D487/04 , A61K31/437 , A61K31/5025 , A61K31/4985 , A61K31/519 , A61P11/06 , A61P11/02 , A61P27/02 , A61P17/00 , A61P11/00 , A61P19/02 , A61P37/08 , A61P17/06 , A61P1/00 , A61P9/10 , A61P9/00 , A61P35/00 , A61P17/02 , A61P43/00 , A61P29/00 , A61P27/16 , C07D471/04
CPC分类号： C07D471/04 , C07D487/04
摘要： Described herein are antagonists of PGD2 receptors. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists of PGD2 receptors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2-mediated conditions or diseases.
摘要翻译： 本文描述的是PGD 2受体的拮抗剂。 还描述了包括本文所述化合物的药物组合物和药物，以及使用PGD2受体单独和与其它化合物组合的这些拮抗剂用于治疗呼吸，心血管和其它PGD2依赖性或PGD2介导的病症的方法 或疾病。
-
50.发明授权Fused heterobicyclo substituted phenyl metabotropic glutamate-5 modulators 失效融合的异二环取代的苯基代谢型谷氨酸-5调节剂公开(公告)号：US07105533B2
公开(公告)日：2006-09-12
申请号：US10527044
申请日：2003-09-09
申请人： Brian Thomas Campbell , Janet Lorraine Gunzer , Benito Munoz , Brian Andrew Stearns , Jean-Michel Andre Vernier , Bowei Wang
发明人： Brian Thomas Campbell , Janet Lorraine Gunzer , Benito Munoz , Brian Andrew Stearns , Jean-Michel Andre Vernier , Bowei Wang
IPC分类号： A61K31/4375 , A61K31/4439 , C07D471/02 , C07D487/02 , C07D513/02
CPC分类号： C07D513/04 , A61K31/137 , A61K31/222 , A61K31/437 , A61K31/4439 , A61K31/444 , A61K31/485 , A61K45/06 , C07D401/10 , C07D471/04 , A61K2300/00
摘要： Phenyl compounds substituted with a fused-heterobicyclo moiety, are mGluR5 modulators useful in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, and panic, as well as in the treatment of pain and other diseases.
摘要翻译： 被稠合 - 杂双环部分取代的苯基化合物是可用于治疗精神病和情绪障碍（例如精神分裂症，焦虑，抑郁和恐慌）以及治疗疼痛和其他疾病的mGluR5调节剂。
-
-
-
-
-
-
-
-
-
搜索结果
50 条记录 (耗时 0.063 秒)
